Quality of life of Lithuanian women with early stage breast cancer

BMC Public Health

Volumn 7, Issue , 2007, Pages

  Bulotiene, Giedre ^a   Veseliunas, Jonas ^a   Ostapenko, Valerijus ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DEMOGRAPHY; EDUCATION; EMOTION; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL QUESTIONNAIRE; HUMAN; INSTRUMENTATION; LITHUANIA; MAJOR CLINICAL STUDY; MARRIAGE; MASTECTOMY; MULTIVARIATE ANALYSIS; OCCUPATION; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL ASPECT; WELLBEING; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; EDUCATIONAL STATUS; EMPLOYMENT; LIFE EVENT; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL ASPECT; SEGMENTAL MASTECTOMY; SICKNESS IMPACT PROFILE; SOCIOECONOMICS;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HUMANS; LIFE CHANGE EVENTS; LITHUANIA; MARITAL STATUS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY, ADJUVANT; SICKNESS IMPACT PROFILE; SOCIOECONOMIC FACTORS;

EID: 34447542870     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-7-124     Document Type: Article

References (16)

1. Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. PA Ganz L Kwan AL Stanton JL Krupnick JH Rowland BE Meyerowitz JE Bower TR Belin, J Natl Cancer Inst 2004 96 5 376 387 14996859
2. Chemotherapy, hormonal therapy and immunotherapy. MT Knobf JV Pasacreta A Valentine R McCorkle, Psycho-oncology New-York: Oxford University Press, Holland JC, 1998 277 288
3. J Turner S Wooding N Cameron, Psychosocial impact of breast cancer: a summary of the literature 1986-1996 Kings Cross, N.S.W.: NHMRC National Breast Cancer Centre 1998
4. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. J Engel J Kerr A Schlesinger-Raab H Sauer D Holzel, Breast J 2004 10 3 223 231 10.1111/j.1075-122X.2004.21323.x 15125749
5. Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer. NK Janz M Mujahid PM Lantz A Fagerlin B Salem M Morrow D Deapen SJ Katz, Qual Life Res 2005 14 6 1467 1479 10.1007/s11136-005-0288-6 16110927
6. Breast cancer. JH Rowland MJ Massie, Psycho-oncology New-York: Oxford University Press, Holland JC, 1998 380 401
7. Validity of cancer-related fatigue instruments. AH Schwartz, Pharmacotherapy 2002 22 11 1433 1441 10.1592/phco.22.16.1433.33690 12432970
8. Assessing quality of life in research and clinical practice. PB Jacobsen K Davis D Cella, Oncology 2002 16 10 133 139 12380963
9. Methods to explain the clinical significance of health status measures. GH Guyatt D Osoba AW Wu KW Wyrwich GR Norman, Mayo Clin Proc 2002 77 371 383 11936935
10. Interpretation of quality of life changes. E Lydick RS Epstein, Qual Life Res 1993 2 221 226 10.1007/BF00435226 8401458
11. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. K Webster D Cella K Yost, Health Qual Life Outcomes 2003 1 79 14678568 10.1186/1477-7525-1-79
12. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. D Cella E Hahn K Dineen, Qual Life Res 2002 11 3 207 221 10.1023/A:1015276414526 12074259
13. The influence of stress management training in HIV disease. NL McCain JM Zeller D Cella PA Urbanski RM Novak, Nursing Res 1996 45 4 246 253 10.1097/00006199-199607000-00009
14. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. D Cella DT Eton JS Lai A Peterman DE Merkel, J Pain Symptom Manage 2002 24 547 561 10.1016/S0885-3924(02)00529-8 12551804
15. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. DT Eton D Cella KJ Yost SE Yount AH Peterman DS Neuberg GN Sledge WC Wood, J Clin Epidemiol 2004 57 9 898 910 10.1016/j.jclinepi.2004.01.012 15504633
16. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anemic cancer patients receiving epoetin alfa. DL Patric DD Gagnon MJ Zagari R Mathijs J Sweetenham, Eur J Cancer 2003 39 335 345 10.1016/S0959-8049(02)00628-7 12565986